CLAIMS

What is claimed is:

1. A composition for use in increasing sclera lysyl oxidase (LOX) activity as part of a treatment of myopia in an eye of a subject in need thereof, comprising a copper-containing agent selected from: copper perchlorate, copper perbromate, copper periodate, and copper permanganate.

2. The composition for use of claim 1, wherein the copper-containing agent is copper perchlorate.

3. The composition for use of claim 1 or claim 2, wherein the composition comprises from 0.001 wt% to 0.1 wt% of the copper-containing agent.

4. The composition for use of any preceding claim, wherein the composition comprises from 0.005 wt% to 0.05 wt% of the copper-containing agent.

5. The composition for use of any preceding claim, wherein the composition comprises from 0.01 mg/mL to 1.0 mg/mL of the copper-containing agent.

6. The composition for use of any preceding claim, wherein the composition comprises from 0.05 mg/mL to 0.5 mg/mL of the copper-containing agent.

7. The composition for use of any preceding claim, wherein the composition comprises from 0.05 mg/mL to 0.25 mg/mL of the copper-containing agent.

8. The composition for use of any preceding claim, wherein the composition further comprises an excipient selected from: a tonicity agent, a solubilizing agent, a thickener, a polymer, a buffer, a pH adjuster, a preservative, and water.

9. The composition for use of any preceding claim, wherein the composition does not comprise an additional active ingredient.

10. The composition for use of any preceding claim, wherein the composition has a tonicity

of from 200 mOsm/kg to 600 mOsm/kg.

11. The composition for use of any preceding claim, wherein the composition has a pH of from 5.0 to 7.8.

12. The composition for use of any preceding claim, wherein the composition is to be administered topically.

13. The composition for use of any preceding claim, wherein the composition is an ophthalmic composition.

14. The composition for use of any preceding claim, wherein the composition is an ointment, gel, thin film or eye drop composition.

15. The composition for use of any one of claims 1-13, wherein the composition is a sustained delivery or depot matrix.

16. The composition for use of any preceding claim, wherein the composition is to be delivered by air-gun delivery or ballistic air delivery.

17. The composition for use of any preceding claim, wherein the composition is to be administered at least once per week per eye in need thereof.

18. The composition for use of claim 17, wherein the composition is to be administered at least once per day per eye in need thereof.

19. The composition for use of claim 18, wherein the composition is to be administered at from 1 to 4 time points per day per eye in need thereof.

20. The composition for use of claim 18, wherein from 5 µl to 100 µl of the composition is to be administered at each time point.

21. The composition for use of any preceding claim, wherein the composition is to be administered for a treatment period of at least about 1 week.

22. The composition for use of any preceding claim, wherein the composition is to be

administered for a treatment period of at least about 6 weeks.

23. The composition for use of any preceding claim, wherein the composition is to be administered for a treatment period of at least about 6 months.

24. The composition for use of any preceding claim, wherein the myopia is progressive myopia.

25. The composition for use of any preceding claim, wherein the myopia is non-progressive myopia.

26. The composition for use of any preceding claim, wherein the subject is a human having an age of at least about 3 years.

27. The composition for use of any preceding claim, wherein the subject is a human having an age of from 3 years to 25 years.

28. The composition for use of any preceding claim, wherein the subject is a human having an age of at least about 25 years.

29. Use of a copper-containing agent selected from: copper perchlorate, copper perbromate, copper periodate, and copper permanganate in the manufacture of a medicament for increasing sclera lysyl oxidase (LOX) activity as part of a treatment of myopia in a subject in need thereof.